<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783051</url>
  </required_header>
  <id_info>
    <org_study_id>226/CNES/BN//PMMF/2020</org_study_id>
    <nct_id>NCT04783051</nct_id>
  </id_info>
  <brief_title>Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)</brief_title>
  <acronym>ULTRAPYRAPREG</acronym>
  <official_title>Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kinshasa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kinshasa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In endemic settings Plasmodium falciparum (Pf) can sequester in the placenta resulting in low&#xD;
      peripheral parasitemia and false negative malaria diagnosis in pregnant women. Intermittent&#xD;
      Preventive Treatment in pregnant women with Sulphadoxine-Pyrimethamine (IPTp-SP) is one of&#xD;
      the World Health Organization's recommended malaria control strategies in sub-Saharan African&#xD;
      countries. The strategy overcomes the risk of misdiagnosis of malaria in pregnant women by&#xD;
      treating them all with SP according to predetermined schedules, but the strategy is now&#xD;
      threatened by the spread of Plasmodium parasite resistant strains. As a necessary&#xD;
      alternative, Intermittent Screening and Treatment in pregnancy (ISTp), aims on the monthly&#xD;
      screening of pregnant women with a malaria rapid diagnostic test (RDT) and the treatment of&#xD;
      positive cases with artemisinin-based combination therapy (ACT) regardless of the presence of&#xD;
      symptoms. The ISTp depends on the performance of the diagnostic tests, and the use of&#xD;
      ultrasensitive RDTs (us-RDTs), which have a higher analytical sensitivity than conventional&#xD;
      RDTs, should improve the efficacy of the strategy.&#xD;
&#xD;
      Unlike IPTp-SP, ISTp prevents overuse of antimalarials and thus limits drug pressure on&#xD;
      malaria parasites. This advantage could be potentiated by using, for pregnant women, an ACT&#xD;
      that is not yet used or should not be used in the field for other strata of the population.&#xD;
      The recently approved new ACT combination, Pyronaridine - Artesunate (Pyramax®) is the ideal&#xD;
      candidate for this purpose.&#xD;
&#xD;
      This study will compare the effects of the ISTp using an us-RDT and Pyramax® (ISTp-US-Py)&#xD;
      with the standard IPTp-SP on maternal malaria indicators (malaria infection, parasite&#xD;
      density), maternal anemia, spontaneous abortions or intrauterine deaths during pregnancy,&#xD;
      fetal morbidity (preterm birth, low birth weight, small for gestational age) and neonatal&#xD;
      mortality at delivery in both study groups through conducting a randomized clinical trial&#xD;
      enrolling second trimester pregnant women in Maternité Esengo Health Center, located in&#xD;
      Kisenso, Kinshasa, the Democratic Republic of the Congo (DRC), a malaria perennial&#xD;
      transmission area.&#xD;
&#xD;
      The results generated from this study will be essential for the National Malaria Control&#xD;
      Program in the selection and implementation of new malaria control policies and addresses the&#xD;
      effectiveness of IPTp-SP decline among pregnant women in the DRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Introduction Malaria is a threat for pregnant women and their offspring in endemic&#xD;
      settings (1, 2). Plasmodium falciparum (Pf) can sequester in the placenta during pregnancy,&#xD;
      resulting in low peripheral parasitemia. As a consequence, malaria diagnostic tests are often&#xD;
      false negative in pregnant women who actually do have a Pf malaria infection (3, 4).&#xD;
&#xD;
      Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine (IPTp-SP)&#xD;
      is one of the World Health Organization (WHO)'s recommended malaria control strategies in&#xD;
      sub-Saharan African countries (2). The IPTp-SP strategy surmounts the potential misdiagnosis&#xD;
      of malaria in pregnant women by treating them all with SP at pre-determined schedules during&#xD;
      the antenatal care (ANC) visits. The efficacy of IPTp-SP is dose dependent and relies on ANC&#xD;
      coverage. However, the spread of Plasmodium SP resistant strains now threatens the efficacy&#xD;
      of the IPTp-SP and can lead to the proliferation of placental resistant parasites in pregnant&#xD;
      women (5-9).&#xD;
&#xD;
      As an alternative for IPTp-SP, Intermittent Screening and Treatment in pregnancy (ISTp) may&#xD;
      be considered as an option (10). ISTp comprises of monthly screening of pregnant women with a&#xD;
      malaria RDT and treatment of positive cases with an artemisinin-based combination therapy&#xD;
      (ACT) regardless of the presence of symptoms. The ISTp depends on the performance of the&#xD;
      diagnostic tests and the use of ultrasensitive RDTs (us-RDTs), which have a higher&#xD;
      sensitivity than conventional RDTs (11, 12), can avoid false negative that would prevent the&#xD;
      method from being effective.&#xD;
&#xD;
      Unlike IPTp-SP, ISTp prevents overuse of antimalarials and, thus, limits drug pressure on&#xD;
      malaria parasites (10). This advantage could be potentiated by using an ACT that is not yet&#xD;
      used or should not be used by the national malaria control for other strata of the population&#xD;
      than pregnant women. Pyronaridine - Artesunate (Pyramax®), a newly approved antimalarial is&#xD;
      the ideal candidate for this purpose in Democratic Republic of Congo (DRC). Pyramax®,&#xD;
      approved for use in malaria endemic countries since 2015, is used in the field to treat&#xD;
      malaria in children and adults (13). There is little information on the safety of Pyramax®&#xD;
      during pregnancy, however, Pyronaridine unintentionally administered successfully treated at&#xD;
      least 40 cases of malaria in late pregnancy (14) and, a review reported that ACTs, although&#xD;
      Pyramax® was not included in, are generally very effective and well tolerated during the&#xD;
      second and third trimesters (15).&#xD;
&#xD;
      The hypothesis of this study is that the ISTp using Pyramax® for the treatment and performed&#xD;
      with the us-RDT (ISTp-US-Py) is non inferior than IPTp-SP for the prevention of maternal&#xD;
      malaria (malaria infection, parasite density), maternal anemia, spontaneous abortions or&#xD;
      intrauterine death during pregnancy, fetal morbidity (premature birth, low birth weight,&#xD;
      small for gestational age) and neonatal mortality at childbirth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of asymptomatic malaria in the 2 study arms</measure>
    <time_frame>6 months</time_frame>
    <description>Asymptomatic malaria is defined as the presence of Pf diagnosed by an us-RDT in the peripheral blood and a T°≤38°C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion symptomatic malaria in the 2 study arms</measure>
    <time_frame>6 months</time_frame>
    <description>Symptomatic malaria is be defined as the presence of Pf diagnosed by an us-RDT in the peripheral blood and a T°≥38°C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of parasitic densities in the 2 study arms</measure>
    <time_frame>6 months</time_frame>
    <description>Parasite density is assessed by the quantification of Pf parasites in the peripheral blood of asymptomatic/symptomatic women by a thin blood smear examined by standard malaria microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of anemia in the 2 study arms</measure>
    <time_frame>6 months</time_frame>
    <description>Anemia is defined as a level of hemoglobin (Hb) &lt;10g/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of spontaneous abortions or intrauterine deaths in the 2 study arms</measure>
    <time_frame>6 months</time_frame>
    <description>Intrauterine death is defined to describe the death of the offspring in the uterus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of fetal morbidities in the 2 study arms</measure>
    <time_frame>6 months</time_frame>
    <description>Fetal morbidity is defined as any of the following: Preterm birth (birth before 37 weeks gestation) and low-birth-weight (birth weight under 2,500 grams)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of the neonatal and early neonatal mortality of the offspring in the 2 study arms</measure>
    <time_frame>28 days</time_frame>
    <description>The early neonatal mortality is defined as infant death at birth or within 7 days of life; And the neonatal mortality is defined as infant death within the first 28 days of life</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Malaria in Pregnancy</condition>
  <arm_group>
    <arm_group_label>IPTp-SP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The IPTp-SP group will be pregnant women who will receive the standard regimen recommended by the Malaria National Control Program (MNCP) at week 16, 28, 32 and 36 of their pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISTp-US-Py</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ISTp-US-Py group will comprise pregnant women who will be screened monthly from the beginning of the 2nd trimester with ultra-sensitive -RDT and who will be treated with Pyramax® if the test is positive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfadoxine pyrimethamine</intervention_name>
    <description>Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine</description>
    <arm_group_label>IPTp-SP</arm_group_label>
    <other_name>IPTp-SP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyramax</intervention_name>
    <description>Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)</description>
    <arm_group_label>ISTp-US-Py</arm_group_label>
    <other_name>ISTp-US-Py</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gestation ≥16 weeks;&#xD;
&#xD;
          2. Age: ≥18 years;&#xD;
&#xD;
          3. Residence within the health facility catchment area;&#xD;
&#xD;
          4. Willing to adhere to study requirements and to deliver at the health facility.&#xD;
&#xD;
          5. Willing to provide written informed consent; if the woman is illiterate, she can&#xD;
             choose an impartial witness, not related to the study, to accompany her during the&#xD;
             informant consent process and they will both sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of allergy to SP or to an ACT&#xD;
&#xD;
          2. An ongoing antibioprophylaxis with cotrimoxazole,&#xD;
&#xD;
          3. Current issue requiring hospital admission (including severe malaria as defined by&#xD;
             WHO)&#xD;
&#xD;
          4. Pregnancy at high risk&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>VIVI TEVUZULA MAKETA, PhD</last_name>
    <phone>00243820582125</phone>
    <email>vmaketangoyi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MELISSA KABENA, MD</last_name>
    <phone>00243815450833</phone>
    <email>melissakabengele14@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternité Esengo</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MELISSA KABENA, MD</last_name>
      <phone>00243815450833</phone>
      <email>melissakabengele14@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <link>
    <url>https://www.pyrapreg.org/about-project/</url>
    <description>The PYRAPREG project</description>
  </link>
  <link>
    <url>https://www.era-learn.eu/network-information/networks/edctp-ii/clinical-trials-and-operational-research-studies-to-optimise-the-use-of-products-for-poverty-related-diseases-in-mothers-newborns-children-and-or-adolescents/efficacy-and-safety-of-a-newly-registered-artemisinin-based-combination-pyronaridine-artesunate-pyramax-r-for-the-treatment-of-uncomplicated-malaria-in-african-pregnant-women</url>
    <description>Clinical trials and operational research studies to optimise the use of products for poverty-related diseases in mothers, newborns, children and/or adolescents</description>
  </link>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf</url>
    <description>Pharmaceuticals R. FANSIDAR. brand of sulfadoxine and pyrimethamine TABLETS 1996</description>
  </link>
  <reference>
    <citation>Nosten F, McGready R, Mutabingwa T. Case management of malaria in pregnancy. Lancet Infect Dis. 2007 Feb;7(2):118-25. Review.</citation>
    <PMID>17251082</PMID>
  </reference>
  <reference>
    <citation>WHO. Guidelines for the treatment of malaria. Third edition2015. 316 p</citation>
  </reference>
  <reference>
    <citation>Anchang-Kimbi JK, Achidi EA, Nkegoum B, Sverremark-Ekström E, Troye-Blomberg M. Diagnostic comparison of malaria infection in peripheral blood, placental blood and placental biopsies in Cameroonian parturient women. Malar J. 2009 Jun 8;8:126. doi: 10.1186/1475-2875-8-126.</citation>
    <PMID>19505312</PMID>
  </reference>
  <reference>
    <citation>Matangila JR, Lufuluabo J, Ibalanky AL, Inocêncio da Luz RA, Lutumba P, Van Geertruyden JP. Asymptomatic Plasmodium falciparum infection is associated with anaemia in pregnancy and can be more cost-effectively detected by rapid diagnostic test than by microscopy in Kinshasa, Democratic Republic of the Congo. Malar J. 2014 Apr 2;13:132. doi: 10.1186/1475-2875-13-132.</citation>
    <PMID>24690179</PMID>
  </reference>
  <reference>
    <citation>van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, ter Kuile FO. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. Lancet Infect Dis. 2013 Dec;13(12):1029-42. doi: 10.1016/S1473-3099(13)70199-3. Epub 2013 Sep 18. Review.</citation>
    <PMID>24054085</PMID>
  </reference>
  <reference>
    <citation>WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017</citation>
  </reference>
  <reference>
    <citation>Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011 Aug 1;53(3):224-30. doi: 10.1093/cid/cir376.</citation>
    <PMID>21765070</PMID>
  </reference>
  <reference>
    <citation>McGready R, White NJ, Nosten F. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG. 2011 Jan;118(2):123-35. doi: 10.1111/j.1471-0528.2010.02810.x. Review.</citation>
    <PMID>21159117</PMID>
  </reference>
  <reference>
    <citation>Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbodji A, Deloron P, Tuikue Ndam N. Submicroscopic Plasmodium falciparum Infections Are Associated With Maternal Anemia, Premature Births, and Low Birth Weight. Clin Infect Dis. 2015 May 15;60(10):1481-8. doi: 10.1093/cid/civ122. Epub 2015 Feb 18.</citation>
    <PMID>25694651</PMID>
  </reference>
  <reference>
    <citation>Esu E, Berens-Riha N, Pritsch M, Nwachuku N, Loescher T, Meremikwu M. Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. Malar J. 2018 Jul 6;17(1):251. doi: 10.1186/s12936-018-2394-2.</citation>
    <PMID>29976228</PMID>
  </reference>
  <reference>
    <citation>Das S, Jang IK, Barney B, Peck R, Rek JC, Arinaitwe E, Adrama H, Murphy M, Imwong M, Ling CL, Proux S, Haohankhunnatham W, Rist M, Seilie AM, Hanron A, Daza G, Chang M, Nakamura T, Kalnoky M, Labarre P, Murphy SC, McCarthy JS, Nosten F, Greenhouse B, Allauzen S, Domingo GJ. Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. Am J Trop Med Hyg. 2017 Nov;97(5):1540-1550. doi: 10.4269/ajtmh.17-0245. Epub 2017 Aug 18.</citation>
    <PMID>28820709</PMID>
  </reference>
  <reference>
    <citation>Vásquez AM, Medina AC, Tobón-Castaño A, Posada M, Vélez GJ, Campillo A, González IJ, Ding X. Performance of a highly sensitive rapid diagnostic test (HS-RDT) for detecting malaria in peripheral and placental blood samples from pregnant women in Colombia. PLoS One. 2018 Aug 2;13(8):e0201769. doi: 10.1371/journal.pone.0201769. eCollection 2018.</citation>
    <PMID>30071004</PMID>
  </reference>
  <reference>
    <citation>Ayyoub A, Methaneethorn J, Ramharter M, Djimde AA, Tekete M, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L. Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1450-8. doi: 10.1128/AAC.02004-15.</citation>
    <PMID>26666916</PMID>
  </reference>
  <reference>
    <citation>Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-Fuhrer I, Rim HJ. Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012 Aug 9;11:270. doi: 10.1186/1475-2875-11-270.</citation>
    <PMID>22877082</PMID>
  </reference>
  <reference>
    <citation>D'Alessandro U, Hill J, Tarning J, Pell C, Webster J, Gutman J, Sevene E. Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018 Apr;18(4):e133-e146. doi: 10.1016/S1473-3099(18)30065-3. Epub 2018 Jan 31. Review.</citation>
    <PMID>29395998</PMID>
  </reference>
  <reference>
    <citation>West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018 Apr 7;391(10128):1378-1390. doi: 10.1016/S0140-6736(18)30291-5. Epub 2018 Mar 29.</citation>
    <PMID>29606364</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kinshasa</investigator_affiliation>
    <investigator_full_name>Vivi Maketa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>IPTp-SP</keyword>
  <keyword>ISTp-Pyramax</keyword>
  <keyword>Kinshasa</keyword>
  <keyword>DR Congo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Document to be share: all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Starting right after the publication</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with any researcher who will ask via any contact of the corresponding author of any publication resulting from this clinical trial</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

